Selma Atalay

5PUBLICATIONS
19CO-AUTHORS
PhysiotherapyPharmacogenomicsClinical pharmacology and therapeuticsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 27, 2022
Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab.

Lara S van der Schoot, Selma Atalay, Marisol E Otero

|Feb 23, 2022
Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial.

Selma Atalay, Sophie E Berends, Hans M M Groenewoud

|Mar 29, 2021
Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab.

Marloes E van Muijen, S Atalay, L J van Vugt

|Dec 28, 2020
Two-year follow-up of a dose reduction strategy trial of biologics adalimumab, etanercept, and ustekinumab in psoriasis patients in daily practice.

S Atalay, J M P A van den Reek, J M M Groenewoud

|May 10, 2017
Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial.

Selma Atalay, Juul M P A van den Reek, Lieke J van Vugt

Pageof 1

Frequent Collaborators

4 joint publications

Juul M P A van den Reek

4 joint publications

Elke M G J de Jong

2 joint publications

J M M Groenewoud

2 joint publications

Peter C M van de Kerkhof